SURVYR

WGS

GeneDx Holdings Corp.
$64.69
+$1.95 (3.11%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-75%-49%-22%+4%+31%Oct 2025Oct 2026Apr 202652w high $170.8752w low $32.21
WGSSPY
Wall St. Highest PT $103.00 (+59.2%) Wall St. Avg PT $93.50 (+44.5%)
$35$68$101$134$168POC $68Hi $103Avg $94
Underwater Drawdown %Max DD -79.4%Current -61.4%
0.0%-79.4%
Relative Strength vs SPY-64.4% vs SPYUnderperforming
+93%0%-93%
1W
−$4.25 (6.16%)
1M
−$21.24 (24.72%)
3M
+$1.00 (1.58%)
6M
+$1.79 (2.85%)
YTD
−$65.37 (50.26%)
1Y
−$72.78 (52.94%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
8 analysts · mean score 1.12
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$64.69
Average target$93.50
+$28.81 (+44.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$83.00
Median$93.50
High$103.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-01 · Guggenheim reiterated Buy on WGS
Reiterated
2026-08-04 · Canaccord Genuity reiterated Buy on WGS
Reiterated
2026-08-04 · BTIG reiterated Buy on WGS
Reiterated
2026-06-29 · Guggenheim reiterated Buy on WGS
Reiterated
2026-06-23 · Piper Sandler reiterated Overweight on WGS
Reiterated
2026-05-05 · Canaccord Genuity reiterated Buy on WGS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.1B
P/E (next 12 months, estimated)57.5
52-week range$32.21 – $170.87
Revenue growth (latest quarter vs a year ago)+11.4%
Dividend yieldNo dividend
Analyst consensusStrong Buy (8)
Average analyst price target$93.50 (+45%)

What they do

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for WGS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

WGS earningsNext report in -2 days
Next report
Tue Oct 27, 2026Time not confirmed
EPS consensus$0.07 range $0.07–$0.08
Revenue consensus$122.9M 8 analysts
Last 4 quarters · EPS vs estimate
Aug 3, 2026$0.01est -$0.19+105.3%Above estimates
May 4, 2026-$0.28est -$0.02−1407.8%Below estimates
Feb 23, 2026$0.14est $0.12+16.7%Above estimates
Oct 28, 2025$0.49est $0.42+15.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:14:09 ET
24-1025-0225-0425-0725-1026-0226-0526-08-0.280.64
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$114.4M+11.4%
2026-03-31$102.3M–
2025-12-31$121.0M–
2025-09-30$116.7M–
2025-06-30$102.7M–

News & catalysts

More news
How Long Can GeneDx Keep Burning Cash?
Trefis · Oct 21
Rating changes
Reiterated
2026-10-01 · Guggenheim reiterated Buy on WGS
Reiterated
2026-08-04 · Canaccord Genuity reiterated Buy on WGS
Reiterated
2026-08-04 · BTIG reiterated Buy on WGS
Reiterated
2026-06-29 · Guggenheim reiterated Buy on WGS
Reiterated
2026-06-23 · Piper Sandler reiterated Overweight on WGS
Reiterated
2026-05-05 · Canaccord Genuity reiterated Buy on WGS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-16
Sell
$106.8K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-16
Sell
$144.5K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-16
Sell
$52.4K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-16
Sell
$5.0K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-16
Sell
$55.2K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-16
Sell
$300.8K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-16
Sell
$406.9K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-16
Sell
$147.8K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-16
Sell
$14.1K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-16
Sell
$155.3K
Feeley Kevin
CHIEF FINANCIAL OFFICER · 2026-09-09
Sell
$108.2K
Stueland Katherine
Director, CHIEF EXECUTIVE OFFICER · 2026-09-09
Sell
$310.9K

Stats refreshed 2026-10-21 18:14:09 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026